Medilink Therapeutics
Unit 101, North Block B3, BioBAY, No. 218, Xinghu Street, Suzhou, Jiangsu, 215000, China
Overview
MediLink Therapeutics develops conjugated drugs and a differentiated proprietary antibody-drug conjugate (ADC) technology platform. The company has invented and patented several novel ADC linker–payload technologies. Its first program was set to begin Phase I clinical trials in both China and the United States this year. The new funding will support clinical development of its new-generation ADC pipeline and early discovery and development of novel conjugated drugs. MediLink has established collaborations with several partners using its proprietary platform. The company was established in 2020 by Dr. Tongtong Xue and is based in Suzhou/Shanghai, China.
- Total raised
- $70M
- Funding rounds
- 1
- Latest round
- Series B
- Latest activity
- Mar 2022
Industries
- Biotechnology
- Genetics
- Therapeutics
Recent funding
Series B
Mar 2022
$70M
Team
Tongtong Xue
Chief Executive Officer & Founder
Sasha Stann
Head of Clinical Operations & Project Management, Project Lead
LinkedIn